PM Tracker

Overall, the 135 large employers surveyed report that costs increases have returned in a big way as care utilization stabilizes at closer to pre-pandemic levels.

The AI system analyzes a sleeping person's breathing patterns for some of the earliest signs of Parkinson’s or to note changes in the severity of the disease over time.

Anne-Virginie Eggimann joins Tessera, a gene writing and rewriting biotech, as chief regulatory officer after 11 years with Bluebird.

Bavarian Nordic has been scrambling to ramp up supply of the only approved monkeypox vaccine, Jynneos, to meet growing global demand. The Danish company’s latest efforts include exploring reusing technically expired doses and shifting production of other vaccines to contractors.

Blue Cross and Blue Shield of Vermont and the Vermont Health Plan filed suit this week against Teva Pharmaceuticals, accusing the company of using some shady tactics to rake in money from its multiple sclerosis drug Copaxone.

In contrast to other up-and-coming robotic surgery systems, one newly cleared by the FDA acts less like an autonomous assistant and more like a surgeon’s extra pair of hands.

Pfizer will team with Zhejiang Huahai for five years. The Chinese firm will produce and sell Paxlovid exclusively in China. The company drew the ire of the FDA in 2018 when it investigated the company for the presence of a suspected carcinogen in a blood pressure medicine it produced.

Providers mostly got what they wanted in a final rule outlining the independent dispute resolution process for out-of-network charges, experts tell Fierce Healthcare.

Third Harmonic Bio is braving the frosty IPO waters. With the weakest quarter for biotech IPOs in years still fresh in the memory, and the proceeds of a $105 million series B still in its bank account, the allergy and inflammatory disease startup has filed to tap public investors for cash to run early-phase trials.

Lewis Carroll’s White Rabbit may have been woefully behind schedule, but Silicon Valley’s Whiterabbit.ai is hoping to keep patients solidly on time for regular breast cancer screenings.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.